Guselkumab vs Risankizumab for Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had Crohn's disease for at least 12 weeks, confirmed by tests like X-rays, biopsies, or a camera exam.
- Your Crohn's is moderate to severe, based on a symptom score between 220 and 450.
- You have active inflammation in your small or large intestine seen during a colonoscopy, with ulcers of a certain size and area.
- You have not had recent surgery (bowel removal within 6 months or other major surgery within 3 months) before starting the study.
- You do not have complications like a blocked intestine, an abscess, a draining stoma, or a fistula that might need surgery soon.
- You do not have cancer or a history of cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study looks at how well guselkumab works for people with moderate to severe Crohn's disease or ulcerative colitis when used as part of regular treatment. It gathers information from real patients to see how the drug performs outside of a research setting.
This trial tests a new medicine called risankizumab for people with Crohn's disease that has caused a narrowing (stricture) in the intestine. It compares risankizumab to another drug, ustekinumab, to see which works better for this type of Crohn's.
This study tracks how well guselkumab (a biologic medication that blocks IL-23, a protein that drives inflammation) works for moderate-to-severe ulcerative colitis or Crohn's disease in everyday clinical practice. Researchers want to understand long-term benefits and safety in real patients.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.